Financial Intelligence
Scored 6/28/2026
Buffett Quality
5.0/10
Lynch Category
Fast Grower
Margin of Safety
—
Acquisition Risk
Not flagged
Owner Earnings
$495M
Recent Signals
20 foundALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 1175 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 495 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 1222 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 921 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
10/10/2018
45%
Watch Reason
S&P 500 / major index component — seeded via EDGAR